Qiagen sweetens Cellestis bid by 7% to speed up completion
This article was originally published in Clinica
Executive Summary
Qiagen has increased its proposed price for the purchase of Australian "pre-molecular" testing specialist Cellestis by 7%, in order to close the matter "as quickly as possible". It is now offering Aus$3.80 ($4.02) per share, or around Aus$365m in total, compared with its previous bid of Aus$3.55 per share, or Aus$341m in total, which it agreed with the Cellestis board in April under a scheme implementation deed (www.clinica.co.uk, 4 April 2011).